European Archives - Page 893 of 1124 - European Medical Journal

Apolipoprotein CIII and Triglycerides in the Necrotic Core Contribute to Plaque Vulnerability in Patients with Stable Coronary Disease

Apolipoprotein CIII (Apo CIII) not only regulates triglyceride (TG) metabolism but also contributes to atherosclerotic formation…

Neutrophils in Acute Coronary Syndrome

Acute coronary syndrome (ACS) encompasses a spectrum of clinical disorders of myocardial ischaemia or infarction, with atherosclerosis leading to…

Left Atrial Parameter to Differentiate Between Physiological or Pathological Process of the left Ventricle

Athletes with pathological hearts are at risk of sudden death through cardiac events. Athletes undergo physiological changes to the heart…

Ectopic Beats: How Many Count?

Premature atrial and ventricular contractions, or ectopic beats, are frequently detected on routine electrocardiogram monitoring.

P-Wave Dispersion and its Association with Hypertension

Hypertension and obesity in adults have been associated with increased P-wave dispersion (PwD). This is postulated due to the correlation of hypertension…

Arrhythmogenic Cardiomyopathy: Genetic Pathology, Inflammatory Syndrome, or both?

Arrhythmogenic cardiomyopathy (ACM) affects mainly young athletes <35 years old and has a potential risk of malignant arrhythmias and sudden death.

Cardiac Cachexia Syndrome

This review gathers evidence to enable recognition of cardiac cachexia and improve identification of patients with terminal heart failure.

RedHill Biopharma Announces Positive Top-Line Results from Phase II Study of BEKINDA® in Patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

Tel-Aviv, Israel/Raleigh, NC, USA, 03 October, 2017 – RedHill Biopharma Ltd. (NASDAQ: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“Red Hill” or the “Company”)…

Immatics Receives $58 Million in Financing to Develop T-Cell Receptor Based Immunotherapies

The Series E funding was supported by existing investors including dievini Hopp Biotech holding, Wellington Partners, AT Impf GmbH and others.

Regulatory Approval in Europe Granted for Synthon’s Glatiramer Acetate 40 mg/ml

Nijmegen, the Netherlands, 05 October, 2017 – Synthon today announced that it has successfully concluded the decentralized procedures for…